News

Misery, thy name is chronic rhinosinusitis


 

EXPERT ANALYSIS FROM THE PULMONARY AND ALLERGY UPDATE

KEYSTONE, COLO. – Just how lousy do patients with medically refractory chronic rhinosinusitis feel in daily life? A lot worse than you might guess.

Patients who elected to undergo endoscopic sinus surgery after failing medical therapy for chronic rhinosinusitis (CRS) rated their own baseline health state on standardized measures as being well below U.S. population norms. Their degree of impairment was similar to the self-rated scores among age- and gender-matched individuals with end-stage renal disease or Parkinson’s disease, according to Dr. Todd T. Kingdom, professor and vice chairman of the department of otolaryngology, head and neck surgery, at the University of Colorado, Denver, and immediate past president of the American Rhinologic Society.

Dr. Todd Kingdom

He cited a 5-year study that prospectively followed 232 adults with CRS who elected to undergo endoscopic sinus surgery (ESS) after failing to improve on medical therapy (Laryngoscope 2011;121:2672-8). Their mean presurgical health state utility value – derived using the Short Form 6D via methods routinely employed by health economists – was 0.65, on a scale in which 0 is death and 1.0 is perfect health.

That was worse than the self-rated scores among patients with heart failure or moderate COPD, as reported in other studies, and only slightly better than the self-rated health of patients awaiting hip replacement or liver transplantation. The U.S. population norm was a score of 0.81, Dr. Kingdom noted at a meeting on allergy and respiratory diseases sponsored by National Jewish Health.

When self-rated health status scores were determined again 6 months or longer after ESS, patients who underwent a revision procedure had a statistically and clinically significant 0.06-point improvement on the 0-1 scale, while those with no prior sinus surgery showed an even more robust 0.09-point gain.

Those are markedly larger improvements than documented in other studies following initiation of drug therapy for Parkinson’s disease, for example, or tumor necrosis factor–inhibitor therapy for psoriasis. Of the specific interventions assessed, only total hip replacement and bariatric surgery resulted in greater self-rated gains in health status than ESS.

In this and other studies, a patient’s baseline clinical phenotype didn’t predict the degree of improvement on quality of life measures following ESS, and gender, age, comorbid asthma, or aspirin-exacerbated respiratory disease did not influence how much benefit a patient would receive from ESS.

Patients with baseline self-reported depression, however, were slightly, albeit statistically significantly, less likely than nondepressed patients to experience significant improvement. And patients who presented without nasal polyps showed significantly more improvement in self-reported health status after ESS than did those with polyps.

Dr. Kingdom reported having no financial conflicts of interest.

bjancin@frontlinemedcom.com

Recommended Reading

Trial immunosuppressive therapy benefits outweigh long-term lymphoma risks in IBD
MDedge Rheumatology
Real-world data backs rivaroxaban for postop VTE prevention
MDedge Rheumatology
CVS to discontinue sale of tobacco products
MDedge Rheumatology
CVS takes health care seriously
MDedge Rheumatology
FDA stops sale of four tobacco products
MDedge Rheumatology
CDC sounds alarm on hospital antibiotic use
MDedge Rheumatology
Two definitions of Gulf War illness recommended
MDedge Rheumatology
Evidence-Based Apps: Texting reminders improved pediatric asthma control
MDedge Rheumatology
CDC: Policy changes could prevent 100,000 deaths a year
MDedge Rheumatology
Survival gains seen with rituximab and mycophenolate in RA lung disease
MDedge Rheumatology